Screener / SEC EDGAR /CIK 0001562088 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Software

Duolingo, Inc. DUOL

Compare with peers Embed
Planned sales, announced before they happen

5 trading plans running, 34 Form 144 notices for $54.2M

10-Q, 10-K and Form 144
Plans running now 5 Natalie Glance, Stephen Chen, Dr. Luis von Ahn, Dr. Severin Hacker
Plans adopted 27 reported since May 10, 2023 Form 144 notices 34 $54.2M the sellers expected to sell

What DUOL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From May 27, 2025 to Dec 31, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Natalie Glance
Chief Engineering Officer
Adopted 10b5-1 plan Sep 4, 2026 10-Q Nov 4, 2026
What the company wrote
On September 4, 2026, Natalie Glance, Chief Engineering Officer, entered into a 10b5-1 sales plan (the “Glance 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, providing for (i) the sale of the net number of shares of Class A common stock underlying 19,283 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 16,866 shares of Class A common stock. The Glance 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2027, (2) the date on which all trades set forth in the Glance 10b5-1 Sales Plan have been executed, or (3) such time as the Glance 10b5-1 Sales Plan is otherwise terminated according to its terms.
Stephen Chen
General Counsel
Adopted 10b5-1 plan Jun 14, 2026 10-Q Aug 6, 2026
What the company wrote
On June 14, 2026, Stephen Chen, General Counsel, entered into a 10b5-1 sales plan (the “Chen 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 12,524 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 12,696 shares of Class A common stock. The Chen 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2027, (2) the date on which all trades set forth in the Chen 10b5-1 Sales Plan have been executed, or (3) such time as the Chen 10b5-1 Sales Plan is otherwise terminated according to its terms.
William "Bing" Gordon
member of our Board of Directors
Ended 10b5-1 plan Jun 9, 2026 10-Q Aug 6, 2026
What the company wrote
On June 9, 2026, William "Bing" Gordon, a member of our Board of Directors, modified his Rule 10b5-1 sales plan that was originally adopted on December 11, 2025. The modified trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and provides for the sale of up to 40,000 shares of the Company’s Class A common stock. The trading arrangement will remain in effect until the earlier of (i) June 30, 2027, (ii) the completion of all authorized transactions, or (iii) termination in accordance with its terms.
Dr. Luis von Ahn
Chief Executive Officer and member of the Company’s Board of Directors
Adopted 10b5-1 plan Jun 2, 2026 10-Q Aug 6, 2026
What the company wrote
On June 2, 2026, Dr. Luis von Ahn, Chief Executive Officer and member of the Company’s Board of Directors, and the Luis von Ahn Foundation, entered into a 10b5-1 sales plan (the “von Ahn 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, pursuant to which a maximum aggregate amount of up to 626,000 shares of the Company’s Class A common stock may be sold, consisting of (i) up to 226,000 shares issuable upon the exercise of vested stock options held by Dr. von Ahn and (ii) up to 400,000 shares held by Dr. von Ahn. Additionally, under the von Ahn 10b5-1 Sales Plan, up to 54,000 shares held by the Luis von Ahn Foundation) may be sold. The von Ahn 10b5-1 Sales Plan will remain in effect until the earlier of (1) September 15, 2027, (2) the date on which all trades set forth in the von Ahn 10b5-1 Sales Plan have been executed, or (3) such time as the von Ahn 10b5-1 Sales Plan is otherwise terminated or expires according to its terms.
William "Bing" Gordon
member of our Board of Directors
Ended 10b5-1 plan Dec 11, 2025 10-K Feb 27, 2026
What the company wrote
On December 11, 2025, William "Bing" Gordon, a member of our Board of Directors, modified his Rule 10b5-1 sales plan (the “Gordon 10b5-1 Sales Plan”) that was originally adopted on June 13, 2025, to extend the expiration date to December 31, 2026. The modified trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and provides for the sale of up to 40,000 shares of the Company’s Class A common stock. The trading arrangement will remain in effect until the earlier of (i) December 31, 2026, (ii) the completion of all authorized transactions, or (iii) termination in accordance with its terms.
Natalie Glance
Chief Engineering Officer
Adopted 10b5-1 plan Sep 15, 2025 10-Q Nov 6, 2025
What the company wrote
On September 15, 2025, Natalie Glance, Chief Engineering Officer, entered into a 10b5-1 sales plan (the “Glance 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) exercise of vested stock options and the associated sale of up to 14,759 shares of the Company’s Class A common stock, (ii) the sale of 3,285 shares of Class A common stock, and (iii) the net number of shares of Class A common stock underlying 16,723 unvested restricted stock units after giving effect to the number of shares to be sold outside of the Glance 10b5-1 Plan to satisfy tax withholding obligations (which net amount is not currently determinable). The Glance 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2026, (2) the date on which all trades set forth in the Glance 10b5-1 Sales Plan have been executed, or (3) such time as the Glance 10b5-1 Sales Plan is otherwise terminated according to its terms.
Dr. Severin Hacker
Chief Technology Officer and member of the Company’s Board of Directors
Adopted 10b5-1 plan Sep 12, 2025 10-Q Nov 6, 2025
What the company wrote
On September 12, 2025, each of Dr. Severin Hacker, Chief Technology Officer and member of the Company’s Board of Directors, the SBH Trust dated March 10, 2020 (“SBH Trust”) and the Severin Hacker Foundation, entered into a joint 10b5-1 sales plan (the “Hacker 10b5-1 Sales Plan”). The Hacker 10b5-1 Sales Plan, which is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, will commence trading once Dr. Hacker’s 10b5-1 sales plan dated September 11, 2024 ends. Under the Hacker 10b5-1 Sales Plan, a maximum aggregate of up to 515,000 shares of the Company’s Class A common stock may be sold, consisting of (i) the net number of shares of Class A common stock issuable upon the exercise of 50,000 vested stock options held by Dr. Severin Hacker that remain unsold pursuant to Mr. Hacker’s 10b5-1 sales plan dated September 11, 2024 (which net amount is not currently determinable), (ii) up to 465,000 shares held by SBH Trust, and (iii) up to 50,000 shares held by the Severin Hacker Foundation). The Hacker 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2027, (2) the date on which all trades set forth in the Hacker 10b5-1 Sales Plan have been executed, or (3) such time as the Hacker 10b5-1 Sales Plan is otherwise terminated or expires according to its terms.
William Gordon
member of our Board of Directors
Adopted 10b5-1 plan Jun 13, 2025 10-Q Aug 7, 2025
What the company wrote
On June 13, 2025, William Gordon, a member of our Board of Directors, entered into a 10b5-1 sales plan (the “Gordon 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing (i) the exercise of vested stock options and the associated sale of up to 10,000 shares of the Company’s Class A common stock, and (ii) the sale of 30,000 shares of Class A common stock. The Gordon 10b5-1 Sales Plan will remain in effect until the earlier of (1) September 30, 2026, (2) the date on which all trades set forth in the Gordon 10b5-1 Sales Plan have been executed, or (3) such time as the Gordon 10b5-1 Sales Plan is otherwise terminated according to its terms.
Dr. Luis von Ahn
Chief Executive Officer
Adopted 10b5-1 plan Jun 11, 2025 10-Q Aug 7, 2025
What the company wrote
On June 11, 2025, Dr. Luis von Ahn, Chief Executive Officer and member of the Company’s Board of Directors, and the Luis von Ahn Foundation, entered into a 10b5-1 sales plan (the “von Ahn 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, pursuant to which a maximum aggregate of up to 431,000 shares of the Company’s Class A common stock may be sold, consisting of (i) up to 226,000 shares issuable upon the exercise of vested stock options held by Dr. von Ahn, (ii) up to 200,000 shares held by Dr. von Ahn, and (iii) up to 5,000 shares held by the Luis von Ahn Foundation). The von Ahn 10b5-1 Sales Plan will remain in effect until the earlier of (1) September 15, 2026, (2) the date on which all trades set forth in the von Ahn 10b5-1 Sales Plan have been executed, or (3) such time as the von Ahn 10b5-1 Sales Plan is otherwise terminated or expires according to its terms.
Robert Meese
Chief Business Officer
Adopted 10b5-1 plan Jun 9, 2025 10-Q Aug 7, 2025
What the company wrote
On June 9, 2025, Robert Meese, Chief Business Officer, entered into a 10b5-1 sales plan (the “Meese 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 3,151 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 18,296 shares of Class A common stock. The Meese 10b5-1 Sales Plan will remain in effect until the earlier of (1) May 29, 2026, (2) the date on which all trades set forth in the Meese 10b5-1 Sales Plan have been executed, or (3) such time as the Meese 10b5-1 Sales Plan is otherwise terminated according to its terms.
Gillian Munson
member of our Board of Directors
Adopted 10b5-1 plan May 27, 2025 10-Q Aug 7, 2025
What the company wrote
On May 27, 2025, Gillian Munson, a member of our Board of Directors, entered into a 10b5-1 sales plan (the “Munson 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for the potential exercise of vested stock options and the associated sale of up to 3,062 shares of the Company’s Class A common stock. The Munson 10b5-1 Sales Plan will remain in effect until the earlier of (1) February 27, 2026, (2) the date on which all trades set forth in the Munson 10b5-1 Sales Plan have been executed, or (3) such time as the Munson 10b5-1 Sales Plan is otherwise terminated according to its terms.
Matthew Skaruppa
Chief Financial Officer
Adopted 10b5-1 plan May 27, 2025 10-Q Aug 7, 2025
What the company wrote
On May 27, 2025, Matthew Skaruppa, Chief Financial Officer, entered into a 10b5-1 sales plan (the “Skaruppa 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 23,429 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable), (ii) the sale of 6,500 shares of Class A common stock and (iii) exercise of vested stock options and the associated sale of up to 1,378 shares of the Company’s Class A common stock. The Skaruppa 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2026, (2) the date on which all trades set forth in the Skaruppa 10b5-1 Sales Plan have been executed, or (3) such time as the Skaruppa 10b5-1 Sales Plan is otherwise terminated according to its terms.
Stephen Chen
General Counsel
Adopted 10b5-1 plan May 27, 2025 10-Q Aug 7, 2025
What the company wrote
On May 27, 2025, Stephen Chen, General Counsel, entered into a 10b5-1 sales plan (the “Chen 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 11,187 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 10,996 shares of Class A common stock. The Chen 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2026, (2) the date on which all trades set forth in the Chen 10b5-1 Sales Plan have been executed, or (3) such time as the Chen 10b5-1 Sales Plan is otherwise terminated according to its terms.
James Shelton
member of our Board of Directors
Adopted 10b5-1 plan Dec 9, 2024 10-K Feb 28, 2025
What the company wrote
On December 9, 2024, James Shelton, a member of our Board of Directors, entered into a 10b5-1 sales plan (the “Shelton 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the potential exercise of vested stock options and the associated sale of up to 20,000 shares of the Company’s Class A common stock, and (ii) the sale of up to 895 shares of Class A common stock underlying unvested restricted stock units. The Shelton 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 29, 2025, (2) the date on which all trades set forth in the Shelton 10b5-1 Sales Plan have been executed, or (3) such time as the Shelton 10b5-1 Sales Plan is otherwise terminated according to its terms.
Robert Meese
Chief Business Officer
Adopted 10b5-1 plan Dec 9, 2024 10-K Feb 28, 2025
What the company wrote
On December 9, 2024, Robert Meese, Chief Business Officer, entered into a 10b5-1 sales plan (the “Meese 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 3,543 restricted stock units received after giving effect to the number of shares automatically sold under the Meese 10b5-1 Sales Plan to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 18,080 shares of Class A common stock shares. The Meese 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2025, (2) the date on which all trades set forth in the Meese 10b5-1 Sales Plan have been executed, or (3) such time as the Meese 10b5-1 Sales Plan is otherwise terminated according to its terms.
Gillian Munson
member of our Board of Directors
Adopted 10b5-1 plan Dec 7, 2024 10-K Feb 28, 2025
What the company wrote
On December 7, 2024, Gillian Munson, a member of our Board of Directors, entered into a 10b5-1 sales plan (the “Munson 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for the potential exercise of vested stock options and the associated sale of up to 5,000 shares of the Company’s Class A common stock. The Munson 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2025, (2) the date on which all trades set forth in the Munson 10b5-1 Sales Plan have been executed, or (3) such time as the Munson 10b5-1 Sales Plan is otherwise terminated according to its terms.
Natalie Glance
Chief Engineering Officer
Adopted 10b5-1 plan Nov 14, 2024 10-K Feb 28, 2025
What the company wrote
On November 14, 2024, Natalie Glance, Chief Engineering Officer, entered into a 10b5-1 sales plan (the “Glance 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 22,099 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 14,855 shares of Class A common stock shares. The Glance 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2025, (2) the date on which all trades set forth in the Glance 10b5-1 Sales Plan have been executed, or (3) such time as the Glance 10b5-1 Sales Plan is otherwise terminated according to its terms.
Dr. Luis von Ahn
Chief Executive Officer and member of the Company’s Board of Directors
Adopted 10b5-1 plan Sep 12, 2024 10-Q/A Dec 16, 2024
What the company wrote
On September 12, 2024, Dr. Luis von Ahn, Chief Executive Officer and member of the Company’s Board of Directors, and the Luis von Ahn Foundation, entered into a 10b5-1 sales plan (the “von Ahn 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, pursuant to which a maximum aggregate of up to 237,750 shares of the Company’s Class A common stock may be sold (up to 219,000 shares by Dr. von Ahn and up to 18,750 shares by the Luis von Ahn Foundation). The von Ahn 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 15, 2025, (2) the date on which all trades set forth in the von Ahn 10b5-1 Sales Plan have been executed, or (3) such time as the von Ahn 10b5-1 Sales Plan is otherwise terminated or expires according to its terms.
Dr. Severin Hacker
Chief Technology Officer and Director
Adopted 10b5-1 plan Sep 10, 2024 10-Q/A Dec 16, 2024
What the company wrote
On September 10, 2024, Dr. Severin Hacker, Chief Technology Officer and Director, entered into a 10b5-1 sales plan (the “Hacker 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for the potential exercise of vested stock options and the associated sale of up to 504,248 shares of the Company’s Class A common stock. The Hacker 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 4, 2025, (2) the date on which all trades set forth in the Hacker 10b5-1 Sales Plan have been executed, or (3) such time as the Hacker 10b5-1 Sales Plan is otherwise terminated according to its terms.
Dr. Severin Hacker
Chief Technology Officer and Director
Adopted 10b5-1 plan Sep 10, 2024 10-Q Nov 7, 2024
What the company wrote
On September 10, 2024, Dr. Severin Hacker, Chief Technology Officer and Director, entered into a 10b5-1 sales plan (the “Hacker 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for the potential exercise of vested stock options and the associated sale of up to 504,248 shares of the Company’s Class A common stock. The Hacker 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 4, 2025, (2) the date on which all trades set forth in the Hacker 10b5-1 Sales Plan have been executed, or (3) such time as the Hacker 10b5-1 Sales Plan is otherwise terminated according to its terms.
Stephen Chen
General Counsel
Adopted 10b5-1 plan May 31, 2024 10-Q Aug 8, 2024
What the company wrote
On May 31, 2024, Stephen Chen, General Counsel, entered into a 10b5-1 sales plan (the “Chen 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the potential exercise of vested stock options and the associated sale of up to 7,382 shares of the Company’s Class A common stock and, (ii) the sale of the net number of shares of Class A common stock underlying 10,898 restricted stock units received after giving effect to the number of shares automatically sold under the Chen 10b5-1 Sales Plan to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (ii) is not determinable), and (iii) the sale of 14,108 shares of Class A common stock shares. The Chen 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2025, (2) the date on which all trades set forth in the Chen 10b5-1 Sales Plan have been executed, or (3) such time as the Chen 10b5-1 Sales Plan is otherwise terminated according to its terms.
Matthew Skaruppa
Chief Financial Officer
Adopted 10b5-1 plan May 22, 2024 10-Q Aug 8, 2024
What the company wrote
On May 22, 2024, Matthew Skaruppa, Chief Financial Officer, entered into a 10b5-1 sales plan (the “Skaruppa 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the potential exercise of vested stock options and the associated sale of up to 69,049 shares of the Company’s Class A common stock, (ii) the sale of the net number of shares of Class A common stock underlying 27,503 restricted stock units received after giving effect to the number of shares automatically sold under the Skaruppa 10b5-1 Sales Plan to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (ii) is not determinable) and (iii) the sale of 27,503 shares of Class A common stock shares. The Skaruppa 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2025, (2) the date on which all trades set forth in the Skaruppa 10b5-1 Sales Plan have been executed, or (3) such time as the Skaruppa 10b5-1 Sales Plan is otherwise terminated according to its terms.
Robert Meese
Chief Business Officer
Adopted 10b5-1 plan Mar 13, 2024 10-Q May 9, 2024
What the company wrote
On December 11, 2023, the 10b5-1 sales plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act entered into by Robert Meese, Chief Business Officer, on September 8, 2023 expired in accordance with its terms upon the sale of the maximum aggregate number of shares of Class A common stock covered by such plan. On March 13, 2024, Mr. Meese entered into a 10b5-1 sales plan (the “Meese 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the potential exercise of vested stock options and the associated sale of up to 17,675 shares of the Company’s Class A common stock. The Meese 10b5-1 Sales Plan will remain in effect until the earlier of (1) July 31, 2025, (2) the date on which an aggregate of 17,675 shares of the Company’s Class A common stock have been sold under the Meese 10b5-1 Sales Plan, or (3) such time as the Meese 10b5-1 Sales Plan is otherwise terminated or expires according to its terms.
Amy Bohutinsky
member of our Board of Directors
Adopted 10b5-1 plan Dec 4, 2023 10-K Feb 29, 2024
What the company wrote
On December 4, 2023, Amy Bohutinsky, member of our Board of Directors, entered into a 10b5-1 sales plan (the “Bohutinsky 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the potential exercise of vested stock options and the associated sale of up to 15,000 shares of the Company’s Class A common stock. The Bohutinsky 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2024, (2) the date on which an aggregate of 15,000 shares of the Company’s Class A common stock have been sold under the Bohutinsky 10b5-1 Sales Plan, or (3) such time as the Bohutinsky 10b5-1 Sales Plan is otherwise terminated or expires according to its terms.
Dr. Luis von Ahn,
Chief Executive Officer
Adopted 10b5-1 plan Nov 30, 2023 10-K Feb 29, 2024
What the company wrote
On November 30, 2023, Dr. Luis von Ahn, Chief Executive Officer, and the Luis von Ahn Foundation, of which Dr. von Ahn is the Director and President, entered into a 10b5-1 sales plan (the “von Ahn 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, pursuant to which a maximum aggregate of 103,000 shares of the Company’s Class A common stock may be sold (up to 80,000 shares by Dr. von Ahn and up to 23,000 by the Luis von Ahn Foundation). The von Ahn 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 15, 2024, (2) the date on which an aggregate of 103,000 shares of the Company’s common stock have been sold under the von Ahn 10b5-1 Sales Plan, or (3) such time as the von Ahn 10b5-1 Sales Plan is otherwise terminated or expires according to its terms.
Stephen Chen
General Counsel
Ended 10b5-1 plan Sep 11, 2023 10-Q Nov 9, 2023
What the company wrote
On September 11, 2023, the 10b5-1 sales plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act entered into by Stephen Chen, General Counsel, on June 2, 2023 expired in accordance with its terms upon the sale of the maximum aggregate number of shares of Class A common stock covered by such plan. On September 15, 2023, Mr. Chen entered into a 10b5-1 sales plan (the “Chen 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the potential exercise of vested stock options and the associated sale of up to 20,000 shares of the Company’s Class A common stock. The Chen 10b5-1 Sales Plan will remain in effect until the earlier of (1) July 31, 2024, (2) the date on which an aggregate of 20,000 shares of the Company’s Class A common stock have been sold under the Chen 10b5-1 Sales Plan, or (3) such time as the Chen 10b5-1 Sales Plan is otherwise terminated or expires according to its terms.
Robert Meese
Chief Business Officer
Adopted 10b5-1 plan Sep 8, 2023 10-Q Nov 9, 2023
What the company wrote
On September 8, 2023, Robert Meese, Chief Business Officer, entered into a 10b5-1 sales plan (the “Meese 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the sale of up to 40,000 shares of the Company’s Class A common stock. The Meese 10b5-1 Sales Plan will remain in effect until the earlier of (1) October 31, 2024, (2) the date on which an aggregate of 40,000 shares of the Company’s common stock have been sold under the Meese 10b5-1 Sales Plan, or (3) such time as the Meese 10b5-1 Sales Plan is otherwise terminated or expires according to its terms.
Natalie Glance
Chief Engineering Officer
Adopted 10b5-1 plan Sep 5, 2023 10-Q Nov 9, 2023
What the company wrote
On September 5, 2023, Natalie Glance, Chief Engineering Officer, entered into a 10b5-1 sales plan (the “Glance 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the sale of up to 60,000 shares of the Company’s Class A common stock. The Glance 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2024, (2) the date on which an aggregate of 60,000 shares of the Company’s Class A common stock have been sold under the Glance 10b5-1 Sales Plan, or (3) such time as the Glance 10b5-1 Sales Plan is otherwise terminated or expires according to its terms.
Matthew Skaruppa
Chief Financial Officer
Ended 10b5-1 plan Jun 9, 2023 10-Q Aug 9, 2023
What the company wrote
On June 9, 2023, Matthew Skaruppa, Chief Financial Officer, modified an existing trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, originally adopted on September 8, 2022 (the “Original Skaruppa 10b5-1 Sales Plan”), to modify the amount of shares, price limits and timing of sales under the plan. The Original Skaruppa 10b5-1 Sales Plan provided for (i) the potential exercise of vested stock options and the associated sale of up to 76,000 shares of the Company’s Class A common stock and (ii) the sale of the net number of shares of Class A common stock underlying 17,315 restricted stock units received after giving effect to the number of shares sold to satisfy tax withholding obligations on each vesting date specified under the Original Skaruppa 10b5-1 Sales Plan (such total number of shares covered under clause (ii) is not determinable). Prior to its termination, 41,764 shares of Class A common Stock were sold pursuant to the Original Skaruppa 10b5-1 Sales Plan, and an aggregate of 44,000 shares of Class A underlying vested stock options remained unsold and 7,551 restricted stock units remained unvested. The modified trading arrangement (the “Skaruppa 10b5-1 Sales Plan”) is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and provides for (i) the potential exercise of vested stock options and the associated sale of up to 100,000 shares of the Company’s Class A common stock and, (ii) the sale of the net number of shares of Class A common stock underlying 20,664 restricted stock units received after giving effect to the number of shares sold to satisfy tax withholding obligations on each vesting date specified under the Skaruppa 10b5-1 Sales Plan (such total number of shares covered under clause (ii) is not determinable), and (iii) the sale of 1,155 shares of Class A common stock shares that remained unsold under the Original Skaruppa 10b5-1 Sales Plan. The Skaruppa 10b5-1 Sales Plan will remain in effect until the earlier of August 14, 2024, (2) the date on which all trades set forth in the Skaruppa 10b5-1 Sales Plan have been executed, or (3) such time as the Skaruppa 10b5-1 Sales Plan is otherwise terminated according to its terms.
Severin Hacker
Chief Technology Officer and director
Adopted 10b5-1 plan Jun 2, 2023 10-Q Aug 9, 2023
What the company wrote
On June 2, 2023, the SBH Trust dated March 10, 2020 (the “SBH Trust”) and the Hacker Charitable Trust, of which Dr. Severin Hacker, Chief Technology Officer and director, is the Trustee, entered into a joint 10b5-1 sales plan (the “Hacker 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, pursuant to which a maximum aggregate of 190,000 shares of the Company’s Class A common stock may be sold (up to 120,000 shares by the SBH Trust and up to 70,000 by the Hacker Charitable Trust). The Hacker 10b5-1 Sales Plan will remain in effect until the earlier of (1) September 30, 2024, (2) upon the completed sale of an aggregate of 190,000 shares of the Company’s Class A common stock have been sold under the Hacker 10b5-1 Sales Plan, or (3) such time as the Hacker 10b5-1 Sales Plan is otherwise terminated according to its terms.
Stephen Chen
General Counsel
Adopted 10b5-1 plan Jun 2, 2023 10-Q Aug 9, 2023
What the company wrote
On June 2, 2023, Stephen Chen, General Counsel, entered into a 10b5-1 sales plan (the “Chen 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the potential exercise of vested stock options and the associated sale of up to 14,167 shares of the Company’s Class A common stock. The Chen 10b5-1 Sales Plan will remain in effect until the earlier of (1) May 31, 2024, (2) the date on which an aggregate of 14,167 shares of the Company’s common stock have been sold under the Chen 10b5-1 Sales Plan, or (3) such time as the Chen 10b5-1 Sales Plan is otherwise terminated according to its terms.
Show the other 23 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 16 filings checked since May 10, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 4, 2026 STEPHEN CHEN
Officer
3,700 $474K
Oct 7, 2026 LUIS VON AHN ARELLANO
Director, Officer, 10% Stockholder
110,046 $16.3M
Sep 24, 2026 LUIS VON AHN ARELLANO
Director, Officer, 10% Stockholder
46,682 $6.8M
Sep 22, 2026 LUIS VON AHN ARELLANO
Director, Officer, 10% Stockholder
3,614 $540K
Sep 21, 2026 LUIS VON AHN FOUNDATION
Director, Officer, 10% Stockholder
34,992 $5.0M
Sep 21, 2026 LUIS VON AHN ARELLANO
Director, Officer, 10% Stockholder
37,366 $5.3M
Sep 16, 2026 LUIS VON AHN ARELLANO
Director, Officer, 10% Stockholder
28,292 $4.4M
Sep 16, 2026 LUIS VON AHN FOUNDATION
Director, Officer, 10% Stockholder
19,008 $2.9M
Sep 14, 2026 STEPHEN CHEN
Officer
8,072 $1.2M
Sep 8, 2026 WILLIAM B. GORDON
Director
20,000 $3.1M
Aug 18, 2026 NATALIE GLANCE
Officer
1,539 $200K
Aug 17, 2026 STEPHEN CHEN
Officer
1,024 $132K
Aug 17, 2026 NATALIE GLANCE
Officer
2,751 $355K
Aug 17, 2026 ROBERT MEESE
Officer
1,354 $175K
May 18, 2026 NATALIE GLANCE
Officer
3,360 $377K
May 18, 2026 STEPHEN CHEN
Officer
1,977 $222K
May 15, 2026 ROBERT MEESE
Officer
1,420 $159K
May 15, 2026 STEPHEN CHEN
Officer
820 $92K
May 15, 2026 NATALIE GLANCE
Officer
1,929 $216K
Feb 18, 2026 STEPHEN CHEN
Officer
1,901 $213K
Feb 18, 2026 MATTHEW SKARUPPA
Officer
3,986 $447K
Feb 18, 2026 NATALIE GLANCE
Officer
3,545 $397K
Feb 17, 2026 MATTHEW SKARUPPA
Officer
1,870 $206K
Feb 17, 2026 NATALIE GLANCE
Officer
1,741 $192K
Feb 17, 2026 STEPHEN CHEN
Officer
896 $99K
Feb 17, 2026 ROBERT MEESE
Officer
1,000 $110K
Dec 12, 2025 THE SEVERIN HACKER FOUNDATIONC/O PHILIP BARTELS
Director, Officer, 10% Stockholder
10,000 $2.0M
Nov 18, 2025 MATTHEW SKARUPPA
Officer
3,059 $545K
Nov 18, 2025 STEPHEN CHEN
Officer
1,514 $270K
Nov 18, 2025 NATALIE GLANCE
Officer
2,471 $441K
Nov 17, 2025 ROBERT MEESE
Officer
1,444 $257K
Nov 17, 2025 NATALIE GLANCE
Officer
2,534 $451K
Nov 17, 2025 STEPHEN CHEN
Officer
1,282 $228K
Nov 17, 2025 MATTHEW SKARUPPA
Officer
2,799 $498K
Show the other 26 notices

From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/DUOL/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.